Roche Susvimo Wins CHMP OK for Wet AMD Continuous Delivery

Roche (RHHBY) announced on July 24, 2026 that the EMA’s Committee for Medicinal Products for Human Use recommended approval of Susvimo (ranibizumab injection) 100 mg/mL for neovascular age-related macular degeneration in the EU. The European Commission typically follows CHMP opinions within 67 days.

RHHBY closed at $54.70 on July 24, up modestly on the announcement.

What Susvimo is

This is not a new molecule. Ranibizumab is the active ingredient in Lucentis, an anti-VEGF antibody that has treated wet AMD since 2006. The innovation is the Port Delivery System, a refillable implant surgically placed in the eye wall that continuously releases the drug. Patients need refills only twice a year instead of the monthly or bimonthly injections that standard anti-VEGF therapy requires.

The CHMP opinion is based on three studies: the Phase 3 Archway trial, the Phase 2 LADDER study, and the open-label Portal extension. Archway showed Susvimo achieved and maintained vision equivalent to monthly intravitreal ranibizumab injections. Portal data showed vision maintenance up to seven years. Approximately 95% of Susvimo patients required no supplemental anti-VEGF treatment.

Why dosing burden matters

Wet AMD is a leading cause of vision loss in older adults, driven by abnormal blood vessel growth under the retina. Roughly 20 million Americans have some form of AMD, with the wet subtype accounting for about 10% of cases. Standard treatment means an eye injection every four to eight weeks, indefinitely. That burden leads to real-world undertreatment: patients skip visits, disease progresses, vision is lost. A device that cuts clinic visits to two per year directly addresses the problem.

Roche competes against Regeneron’s Eylea franchise and Vabysmo (faricimab) in ophthalmology. Both are under pricing and biosimilar pressure. Susvimo’s dosing convenience is the differentiator, not the drug itself.

US context and the recall

The FDA approved Susvimo for nAMD in October 2021, then pulled it from the market in 2022 after device leaks were reported. Roche reintroduced the product in July 2024 with a redesigned implant. The CHMP opinion validates the safety profile of the updated device and could support US adoption, where Roche also holds approvals for diabetic macular edema and diabetic retinopathy with Susvimo.

What to watch

The European Commission decision is the next step. In the US, watch Susvimo’s uptake trajectory against Eylea biosimilars and Vabysmo. The refillable implant requires surgical insertion, which is a adoption barrier Eylea and Vabysmo do not face. For more on how regulatory decisions move biotech stocks, see our guide to PDUFA dates.

What It Means for the Trade

A CHMP opinion for a product already FDA-approved is incremental for Roche — RHHBY at $54.70 is not trading on EU wet AMD, and the modest move was the correct calibration. What the opinion actually does is extend the runway for Susvimo to recoup its difficult US history. The 2022 recall for device leaks forced a redesign and a two-year relaunch; European approval of the updated implant is independent validation that the safety question is behind the product. That matters for the retinal specialist community, whose memory of the recall is the product’s biggest commercial obstacle.

The competitive context is the real story. Eylea faces biosimilar erosion, Vabysmo is winning share on extended dosing, and both are squeezing ranibizumab-based products. Susvimo is Roche’s answer in a segment where convenience is the currency: twice-yearly refills versus six to thirteen injections per year. The 95% of patients requiring no supplemental anti-VEGF in the Portal extension is the statistic that sells the device to tired patients — but only if the surgical insertion hurdle clears.

Mechanism and Market Context

The Port Delivery System is a device-drug combination, and that cuts both ways. The refillable implant continuously releases ranibizumab — a 2006-era molecule — achieving with 1990s biology what newer drugs achieve with better pharmacology. Archway showed vision equivalent to monthly injections, Portal showed maintenance up to seven years, and the EU package now rests on the same three-study backbone as the US approval. The innovation is entirely in delivery, which means the moat is a device patent and surgical workflow, not molecular novelty.

The adoption barrier deserves emphasis. Wet AMD patients are elderly, and Susvimo requires an outpatient surgical procedure plus periodic refills through the implant. Retina specialists have spent two decades avoiding anything resembling ocular surgery in their injection clinics. Uptake will concentrate in the highest-burden patients — those struggling with monthly visit compliance — which is exactly the undertreated population where the device’s benefit is largest.

Risks and What Could Go Wrong

1. Recall memory. One device-safety headline in an implanted product re-triggers the 2022 narrative instantly; the EU approval helps, but specialist trust rebuilds slowly.
2. Surgical economics. Reimbursement for implantation and refills must align with what injection-based management pays, or adoption stalls at the hospital level.
3. Vabysmo’s trajectory. Extended-interval dosing with no surgery keeps raising the convenience bar; Susvimo’s window is the gap between four-to-eight-week injections and twice-yearly refills, and that gap narrows every year.
4. Biosimilar price collapse. As anti-VEGF injections commoditize, the price differential makes an implanted branded product harder to defend.

This is a niche product with a real niche — size it accordingly, and do not treat a CHMP opinion as a catalyst.